AIDD, AI Drug Development Division, is a part of NEC Corporate’s Global Innovation Unit, in Tokyo, Japan, It will continue to focus on development of new technology, through continued academic collaborations and new forge collaborations in future. It would also support NEC Bio initiatives in the future.

The main focus of NEC Bio will be to streamline all AI drug research and development activities and strengthen NEC’s global position in this area. NEC Bio’s mission is to bring novel therapies to patients across the globe, to improve their quality of life and health outcomes. It will achieve this mission by empowering NEC OncoImmunity to continue its cutting-edge research in the AI drug development domain and enable NEC Bio Therapeutics, to focus on clinical development of pipeline assets

NEC Bio Therapeutics, established in Manheim, Germany, will focus on clinical strategy and development, as well as planning and execution of clinical trials in oncology area.